Real-World Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients With Chronic Migraine.

Mechtler, Laszlo; Saikali, Nicolas; McVige, Jennifer; Hughes, Olivia; Traut, Alexandra; Adams, Aubrey Manack

Mechtler, Laszlo; Saikali, Nicolas; McVige, Jennifer; Hughes, Olivia; Traut, Alexandra; Adams, Aubrey Manack.

Afiliación

Mechtler L; DENT Neurologic Institute, Amherst, NY, United States.
Saikali N; DENT Neurologic Institute, Amherst, NY, United States.
McVige J; DENT Neurologic Institute, Amherst, NY, United States.
Hughes O; ICON plc, Boston, MA, United States.
Traut A; Allergan, an AbbVie Company, Irvine, CA, United States.
Adams AM; Allergan, an AbbVie Company, Irvine, CA, United States.

Front Neurol ; 12: 788159, 2021.

Article en En | MEDLINE | ID: mdl-35069416

Palabras clave

calcitonin gene-related peptide; combination treatment; headache; migraine; onabotulinumtoxinA; prevention; safety

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Front Neurol Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google